1. Scrip
  2. >>New Products

Zydus moves into Mexico with first launches

 
• By Anju Ghangurde

Zydus Cadila expects to launch its first wave of products in Mexico – one of its future strategic "home markets" – next month, a top executive at the Indian firm has told Scrip. Zydus' push into Mexico comes amid the implementation of a string of favorable regulatory reforms in the pharmaceutical segment by the Latin American nation over the recent past.

Zydus Cadila expects to launch its first wave of products in Mexico – one of its future strategic "home markets" – next month, a top executive at the Indian firm has told Scrip. Zydus' push into Mexico comes amid the implementation of a string of favorable regulatory reforms in the pharmaceutical segment by the Latin American nation over the recent past.

Zydus' chief operating officer and executive director, Ganesh Nayak, said that the company had four approvals in place in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from Scrip

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Executives On The Move: Three New CEOs And CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.